Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.
Adult
Aspergillus
Bacteria
/ genetics
Basidiomycota
Candida
Case-Control Studies
DNA, Ribosomal Spacer
/ genetics
Debaryomyces
Diarrhea
/ microbiology
Dysbiosis
/ microbiology
Entomophthorales
Eurotium
Female
Fungi
Gastrointestinal Microbiome
/ genetics
Humans
Irritable Bowel Syndrome
/ microbiology
Male
Microbial Interactions
Middle Aged
Mycobiome
/ genetics
Mycosphaerella
RNA, Ribosomal, 16S
/ genetics
bacterial-fungal interaction
diarrhea
fungal dysbiosis
irritable bowel syndrome
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
24
12
2019
revised:
11
03
2020
accepted:
30
04
2020
pubmed:
26
5
2020
medline:
16
9
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Little is known about intestinal fungi in IBS patients whose gut bacteria have been investigated a lot. In order to explore causal relationship between IBS and gut mycobiome, and use gut fungi to diagnose or even treat IBS, further characterization of it in IBS is required. Fifty-five diarrhea-predominant IBS (D-IBS) patients fulfilling Rome III criteria, and 16 healthy controls (HC) were recruited. Fresh fecal samples were collected and used for 16s rRNA and ITS2 high-throughput sequencing. Diversity and composition of gut bacteria and fungi, as well as bacterial-fungal interactions in D-IBS patients, were characterized. Specific fungal taxa differentiating D-IBS from HC were recognized by LEfSe and RandomForest methods, and their association with clinical symptoms was assessed by Spearman's correlation. Diarrhea-predominant irritable bowel syndrome patients showed abnormal (IBS-dysbiosis) or normal (HC-like IBS) fecal bacterial structure and diversity compared with healthy controls. However, fecal fungal signatures differed absolutely between D-IBS and HC, which indicated a more susceptible alteration of gut fungi than bacteria in D-IBS. Fecal fungi showed significant correlations with IBS symptoms, especially Mycosphaerella, Aspergillus, Sporidiobolus, and Pandora which were identified to potentially differentiate D-IBS from HC. Moreover, compared with HC there were markedly declined bacterial-fungal interactions in D-IBS, in which Candida changed from negative to positive correlations with bacteria, and Eurotium changed from positive correlations to irrelevance, while Debaryomyces gained negative correlations with bacteria. Gut fungal dysbiosis and altered bacterial-fungal interactions were present in patients with D-IBS, and gut fungi could be used to diagnose D-IBS.
Sections du résumé
BACKGROUND
Little is known about intestinal fungi in IBS patients whose gut bacteria have been investigated a lot. In order to explore causal relationship between IBS and gut mycobiome, and use gut fungi to diagnose or even treat IBS, further characterization of it in IBS is required.
METHODS
Fifty-five diarrhea-predominant IBS (D-IBS) patients fulfilling Rome III criteria, and 16 healthy controls (HC) were recruited. Fresh fecal samples were collected and used for 16s rRNA and ITS2 high-throughput sequencing. Diversity and composition of gut bacteria and fungi, as well as bacterial-fungal interactions in D-IBS patients, were characterized. Specific fungal taxa differentiating D-IBS from HC were recognized by LEfSe and RandomForest methods, and their association with clinical symptoms was assessed by Spearman's correlation.
RESULTS
Diarrhea-predominant irritable bowel syndrome patients showed abnormal (IBS-dysbiosis) or normal (HC-like IBS) fecal bacterial structure and diversity compared with healthy controls. However, fecal fungal signatures differed absolutely between D-IBS and HC, which indicated a more susceptible alteration of gut fungi than bacteria in D-IBS. Fecal fungi showed significant correlations with IBS symptoms, especially Mycosphaerella, Aspergillus, Sporidiobolus, and Pandora which were identified to potentially differentiate D-IBS from HC. Moreover, compared with HC there were markedly declined bacterial-fungal interactions in D-IBS, in which Candida changed from negative to positive correlations with bacteria, and Eurotium changed from positive correlations to irrelevance, while Debaryomyces gained negative correlations with bacteria.
CONCLUSIONS
Gut fungal dysbiosis and altered bacterial-fungal interactions were present in patients with D-IBS, and gut fungi could be used to diagnose D-IBS.
Substances chimiques
DNA, Ribosomal Spacer
0
RNA, Ribosomal, 16S
0
Banques de données
ChiCTR
['ChiCTR-OPC-15007624']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13891Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Thompson WG, Longstreth GF, Drossman DA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45(Suppl 2):ii43-ii47.
Sultan S, Malhotra A. Irritable bowel syndrome. Ann Intern Med. 2017;166:ITC81-ITC96.
Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol. 2014;11:497-505.
Tap J, Derrien M, Törnblom H, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152:111-123.e8.
Giada De Palma MDJL, Jun LU, Dang VT. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice. Sci Transl Med. 2017;9:eaaf6397.
Rm C. Low FODMAP diet for IBS. Gastroenterology. 2018;154:1547.
Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22-32.
Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153:448-459.e8.
Ford AC, Harris LA, Lacy BE, Quigley EM M, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48:1044-1060.
Huang HL, Chen HT, Luo QL, et al. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. J Dig Dis. 2019;20(8):401-408.
Limon JJ, Skalski JH, Underhill DM. Commensal fungi in health and disease. Cell Host Microbe. 2017;22:156-165.
Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut. 2017;66:1039-1048.
Limon JJ, Tang J, Li D, et al. Malassezia is associated with Crohn's disease and exacerbates colitis in mouse models. Cell Host Microbe. 2019;25(3):377-388.e6.
Botschuijver S, Roeselers G, Levin E, et al. Intestinal fungal dysbiosis is associated with visceral hypersensitivity in patients with irritable bowel syndrome and rats. Gastroenterology. 2017;153:1026-1039.
Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology. 2006;130:1480-1491.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370.
Zhou MI, Rong R, Munro D, et al. Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing. PLoS ONE. 2013;8:e61516.
Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of highthroughput community sequencing data. Nat Methods. 2010;7:335-336.
Li G, Yang M, Jin YU, et al. Involvement of shared mucosal-associated microbiota in the duodenum and rectum in diarrhea-predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2018;33:1220-1226.
Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods. 2013;10:996-998.
Rognes T, Flouri T, Nichols B, et al. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584.
URMAS KOLJALG RHN. Towards a unified paradigm for sequence-based identification of fungi. Mol Ecol. 2013;22:5271-5277.
Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60.
Liaw AWM. Classification and regression by randomForest. R News. 2002;2:18-22.
Kuhn MWJ, Weston S. Caret: classification and regression training. R Package. 2016;6:0-73.
Qiu IWK, Long W. A comparative assessment of the influences of human impacts on soil cd concentrations based on stepwise linear regression, classifcation and regression tree, and random Forest Models. PLoS ONE. 2016;11:e0151131.
Feng Q, Liang S, Jia H, et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun. 2015;6:6528.
Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014-1023.
Langille MGI, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814-821.
Labus JS, Hollister EB, Jacobs J, et al. Differences in gut microbial composition correlate with regional brain volumes in irritable bowel syndrome. Microbiome. 2017;5:49.
Jeffery IB, O'Toole PW, Öhman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61:997-1006.
Clemente J, Ursell L, Parfrey L, et al. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258-1270.
Remely M, Haslberger AG. The microbial epigenome in metabolic syndrome. Mol Aspects Med. 2017;54:71-77.
Indiani CMDSP, Rizzardi KF, Castelo PM, et al. Childhood obesity and firmicutes/bacteroidetes ratio in the Gut microbiota: a systematic review. Child Obes. 2018;14:501-509.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444:1022-1023.
Zhuang X, Tian Z, Li LI, et al. Fecal microbiota alterations associated with diarrhea-predominant irritable bowel syndrome. Front Microbiol. 2018;9:1600.
Hester SN, Mastaloudis A, Gray R, et al. Efficacy of an anthocyanin and prebiotic blend on intestinal environment in obese male and female subjects. J Nutr Metab. 2018;2018:7497260.
Chen Y-H, Bai J, Wu DI, et al. Association between fecal microbiota and generalized anxiety disorder: severity and early treatment response. J Affect Disord. 2019;259:56-66.
Hu S, Li A, Huang T, et al. Gut microbiota changes in patients with bipolar depression. Adv Sci. 2019;6:1900752.
Wang L-W, Wang J-L, Chen J, et al. A novel derivative of (-)mycousnine produced by the endophytic fungus Mycosphaerella nawae, exhibits high and selective immunosuppressive activity on T cells. Front Microbiol. 2017;8:1251.
Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1:133-146.
Padhi S, Masi M, Panda SK, et al. Antimicrobial secondary metabolites of an endolichenic Aspergillus niger isolated from lichen thallus of Parmotrema ravum. Nat Prod Res. 2019;1-8.
Du C, Ying D, Guo Y, et al. Ameliorating effects of Sporidiobolus pararoseus extract on dyslipidemia in mice with high fat diet induced obesity. Biochem Cell Biol. 2018;96:695-701.
Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369-2379.
Dollive S, Chen Y-Y, Grunberg S, et al. Fungi of the murine gut: episodic variation and proliferation during antibiotic treatment. PLoS ONE. 2013;8:e71806.
Imai T, Inoue R, Kawada Y, et al. Characterization of fungal dysbiosis in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2019;54:149-159.
Taylor PR, Tsoni SV, Willment JA, et al. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31-38.
Moyes DL, Wilson D, Richardson JP, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature. 2016;532:64-68.
Richardson JP, Mogavero S, Moyes DL, et al. Processing of Candida albicans Ece1p is critical for candidalysin maturation and fungal virulence. MBio. 2018;9:e02178-e2217.
Kasper L, König A, Koenig P-A, et al. The fungal peptide toxin Candidalysin activates the NLRP3 inflammasome and causes cytolysis in mononuclear phagocytes. Nat Commun. 2018;9:4260.
He LU, Long C, Liu Y, et al. Effects of Debaryomyces hansenii treatment on intestinal microorganisms in mice with antibiotics-induced diarrhea. 3 Biotech. 2017;7:347.
Sovran B, Planchais J, Jegou S, et al. Enterobacteriaceae are essential for the modulation of colitis severity by fungi. Microbiome. 2018;6:152.